Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21487311 | 0.81 | HTT (0.52) | HTTSMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL8423468 | 0.81 | GPR35 (0.54) | HTTSMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL8980342 | 0.79 | HTT (0.61) | HTTSMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL27303263 | 0.78 | HTT (0.59) | HTTSMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL11435996 | 0.78 | HTT (0.49) | HTTSMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL17786526 | 0.77 | DBH (0.53) | HTTSMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL17786528 | 0.77 | DBH (0.53) | HTTSMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL31392530 | 0.77 | GPR35 (0.69) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL4132017 | 0.77 | GPR35 (0.69) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL11067720 | 0.77 | GPR35 (0.61) | HTTSMN1; SMN2ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016083490-A1 | COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES | REMYND NV (BE) | 2016-06-02 | — | — | WO | disclosed |
| US-7547708-B2 | N-sulfamoyl-N′-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALS, INC. (DE) | 2009-06-16 | — | — | US | disclosed |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALSS GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SOLVAY PHARMACEUTICALSS GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| WO-2007054580-A1 | N-SULFAMOYL-N’-BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-05-18 | — | — | WO | disclosed |
| US-6683095-B2 | ANTICARCINOGENIC AGENTS; ANTIPROLIFERATION AGENTS | LG LIFE SCIENCES LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| CN-1433410-A | CDK inhibitors having 3-hydroxychromen-4-one structure | LG LIFE SCIENCES CO LTD (KR) | 2003-07-30 | — | — | CN | disclosed |
| US-20030125356-A1 | Cdk inhibitors having 3-hydroxychromen-4-one structure | LG LIFE SCIENCES LTD. (KR) | 2003-07-03 | — | — | US | disclosed |
| EP-1280789-A1 | CDK INHIBITORS HAVING 3-HYDROXYCHROMEN-4-ONE STRUCTURE | LG Life Sciences Ltd. (KR) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083469-A1 | CDK INHIBITORS HAVING 3-HYDROXYCHROMEN-4-ONE STRUCTURE | LG LIFE SCIENCES LTD. (KR) | 2001-11-08 | — | — | WO | disclosed |
| US-4442115-A | ANTI-ASTHMA | MAY & BAKER LIMITED (GB) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125356-A1 | Cdk inhibitors having 3-hydroxychromen-4-one structure | CDK4, CDK3, CDK6 | HTT 2987/4885SMN1; SMN2 4162/4885ALDH1A1 1157/4885 |
| US-20070117823-A1 | N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof | SCN2A, NAPEPLD, SCN5A | HTT 1462/4885SMN1; SMN2 744/4885ALDH1A1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.